American Capital And Its Affiliates Invest $10.7 Million In
Portfolio Company Halt Medical
BETHESDA, Md., Jan. 8,
2013 /PRNewswire/ -- American Capital, Ltd. (Nasdaq: ACAS)
("American Capital") announced today that in December 2012 it invested $6.2 million ($10.7
million including investments by affiliates) in portfolio
company Halt Medical, Inc., a medical device company focused on
women's health. The investment supports the commercialization
of the Acessa™ System, a newly FDA cleared medical device to treat
uterine fibroids.
"American Capital is pleased to be a part of Halt Medical's
continued growth and success in treating uterine fibroids with this
additional financing," said Gordon O'Brien, American Capital
President, Specialty Finance and Operations. "The additional
capital will support the Company's commercialization of its new
revolutionary medical technology for treating millions of women
suffering from uterine fibroids, the Acessa™ System. The
Acessa™ System is an alternative to hysterectomy for fibroid
patients and is the first FDA cleared product used by gynecologists
to treat all fibroid symptoms and types."
American Capital and an affiliate first invested in Halt Medical
in May 2007. Halt Medical is a medical device company focused
on establishing a new standard of care for women with symptomatic
uterine fibroids. The Company has developed and launched the
Acessa™ System and Procedure, using radiofrequency energy to
destroy uterine fibroids. The results of both U.S. and
international trials have led to the clearance of the product by
the FDA for use in percutaneous, laparoscopic coagulation and
ablation of soft tissue, including treatment of symptomatic uterine
fibroids under laparoscopic ultrasound guidance. In addition,
the System has CE marking in the European Union and is licensed for
sale in Canada. The Company
was founded in 2004 and is located in Brentwood, CA.
"We are delighted that American Capital has chosen to once again
lead financing for this critical new medical device," said
Jeff Cohen, Halt Medical Chief
Executive Officer. "Since the start of our relationship,
American Capital has been very supportive of our business model and
technology. This additional investment will enable us to
continue to build out the commercial side of our business and
expand our market presence in the U.S. and
internationally."
American Capital and its affiliated funds have invested
approximately $31 billion in over 540
portfolio companies both directly and in support of leading
financial partners in change of control transactions. For
more information about American Capital's portfolio, go to
http://www.americancapital.com/Pages/our_portfolio/our_portfolio.aspx.
ABOUT AMERICAN CAPITAL
American Capital is a publicly
traded private equity firm and global asset manager. American
Capital, both directly and through its asset management business,
originates, underwrites and manages investments in middle market
private equity, leveraged finance, real estate and structured
products. American Capital manages $18.6 billion of assets, including assets on its
balance sheet and fee earning assets under management by affiliated
managers, with $118 billion of total
assets under management (including levered assets). From its
eight offices in the U.S. and Europe, American Capital and its affiliate,
European Capital, will consider investment opportunities from
$10 million to $500 million.
For further information, please refer to
www.AmericanCapital.com.
This press release contains forward-looking statements. The
statements regarding expected results of American Capital are
subject to various factors and uncertainties, including the
uncertainties associated with the timing of transaction closings,
changes in interest rates, availability of transactions, changes in
regional, national or international economic conditions, or changes
in the conditions of the industries in which American Capital has
made investments.
Contact:
Gordon O'Brien, President, Specialty Finance and Operations 301
951 6122
SOURCE American Capital, Ltd.